The Gut Regulated Associations of Neuronal Signalling in High Blood Pressure (GRAINS-BP) clinical trial investigates hypertension in adults with elevated blood pressure. The study will involve 29 participants with untreated hypertension, utilizing a double-blind, cross-over design.
Key Clinical Findings
Participants will receive HAMSA/B, a high amylose maize starch enriched with acetate and butyrate, as a shake administered twice daily for 48 days. Assessments will occur at the Alfred Hospital in Melbourne, Australia, including measurement of muscle sympathetic nerve activity (MSNA) and electrocardiogram (ECG) at baseline. During the intervention period, faecal, urine, and blood samples will be collected to analyze microbiome, cardiometabolic, renal, and immune profiles.
Outcome Measures
Statistical analyses will examine treatment effects and correlations among these profiles. The primary outcome measures change in autonomic nervous system activity. Secondary outcomes include 24-hour blood pressure, gut microbiome composition, short-chain fatty acid levels, immune cell profiles, gastrointestinal transit time, quality of life, anxiety and depression symptoms, cognitive function, gut barrier integrity, and circulating micro- and nanoplastics. MSNA and ECG were key measurements.